Pfizer (PFE) CEO Albert Bourla said the company’s dispute with activist firm Starboard Value isn’t “an aggressive situation,” months after the investor disclosed a stake in the company and questioned his management, Damian Garde of Bloomberg reports. “I don’t underestimate anyone,” Bourla said at the JPMorgan Healthcare Conference in San Francisco. “I respect Starboard, and I try to be engaged with them. If they have good ideas, we will do it.” Bourla said Starboard recommended Pfizer make some changes “on the margins,” but has not called for cost cuts, board changes, or a breakup of the company.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer study impact on CG Oncology to be minimal, says H.C. Wainwright
- Pfizer announces ‘positive’ results from Phase 3 CREST trial of sasanlimab
- Drugmakers Raise the Prices on 583 Products to Start 2025
- Exxon and Shell cautious on Q4, Flutter cuts guidance: Morning Buzz
- Trump Trade: New administration to invest $20B to build data centers